Search

Your search keyword '"Leebeek, Frank W. G."' showing total 726 results
Start Over Author "Leebeek, Frank W. G."
726 results on '"Leebeek, Frank W. G."'

1. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

Author

Atiq, Ferdows, Blok, Robin, van Kwawegen, Calvin B., Doherty, Dearbhla, Lavin, Michelle, van der Bom, Johanna G., O'Connell, Niamh M., de Meris, Joke, Ryan, Kevin, Schols, Saskia E. M., Byrne, Mary, Heubel-Moenen, Floor C. J. I., van Galen, Karin P. M., Preston, Roger J. S., Cnossen, Marjon H., Fijnvandraat, Karin, Baker, Ross I., Meijer, Karina, James, Paula, Di Paola, Jorge, Eikenboom, Jeroen, Leebeek, Frank W. G., and O'Donnell, James S.

Published
2024
Full Text
View/download PDF

2. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Author

Castaman, Giancarlo, Crary, Shelley E, Escobar, Miguel, Gomez, Esteban, Haley, Kristina M, Hermans, Cedric R J R, Kampmann, Peter, Kazmi, Rashid, Key, Nigel S, Klamroth, Robert, Konkle, Barbara A, Kruse-Jarres, Rebecca, Lattimore, Susan, Lemons, Richard, Meijer, Karina, O'Connell, Niamh, Quon, Doris V, Raheja, Priyanka, Symington, Emily, Verhamme, Peter, Visweshwar, Nathan, von Drygalski, Annette, Wang, Michael, Wheeler, Allison P, White, Shanna, Young, Guy, Coppens, Michiel, Pipe, Steven W, Miesbach, Wolfgang, Astermark, Jan, Recht, Michael, van der Valk, Paul, Ewenstein, Bruce, Pinachyan, Karen, Galante, Nicholas, Le Quellec, Sandra, Monahan, Paul E, and Leebeek, Frank W G

Published
2024
Full Text
View/download PDF

4. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Author

Coppens, Michiel, primary, Pipe, Steven W, additional, Miesbach, Wolfgang, additional, Astermark, Jan, additional, Recht, Michael, additional, van der Valk, Paul, additional, Ewenstein, Bruce, additional, Pinachyan, Karen, additional, Galante, Nicholas, additional, Le Quellec, Sandra, additional, Monahan, Paul E, additional, Leebeek, Frank W G, additional, Castaman, Giancarlo, additional, Crary, Shelley E, additional, Escobar, Miguel, additional, Gomez, Esteban, additional, Haley, Kristina M, additional, Hermans, Cedric R J R, additional, Kampmann, Peter, additional, Kazmi, Rashid, additional, Key, Nigel S, additional, Klamroth, Robert, additional, Konkle, Barbara A, additional, Kruse-Jarres, Rebecca, additional, Lattimore, Susan, additional, Lemons, Richard, additional, Meijer, Karina, additional, O'Connell, Niamh, additional, Quon, Doris V, additional, Raheja, Priyanka, additional, Symington, Emily, additional, Verhamme, Peter, additional, Visweshwar, Nathan, additional, von Drygalski, Annette, additional, Wang, Michael, additional, Wheeler, Allison P, additional, White, Shanna, additional, and Young, Guy, additional

Published
2024
Full Text
View/download PDF

5. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

Author

Cnossen, Marjon H., Leebeek, Frank W.G., Mathôt, Ron A.A., Fijnvandraat, Karin, Coppens, Michiel, Meijer, Karina, Kruip, Marieke J.H.A., Polinder, Suzanne, Lock, Janske, Hazendonk, Hendrika C.A.M., Van Moort, Iris, Heijdra, Jessica M., Goedhart, Marie C.H.J., Al Arashi, Wala, Preijers, Tim, De Jager, Nico C.B., Bukkems, Laura H., Cloesmeijer, Michael E., Janssen, Alexander, Tamminga, Rienk Y.J., Brons, Paul, Schols, Saskia E.M., Eikenboom, Jeroen C.J., Van der Meer, Felix J.M., Schutgens, Roger E.G., Fischer, Kathelijne, Van Galen, Karin P.M., Beckers, Erik E.A.M., Heubel-Moenen, Floor C.J.I., Nieuwenhuizen, Laurens, Ypma, Paula, Driessens, Mariëtte H.E., Van Vliet, Ineke, Collins, Peter W., Liesner, Ri, Chowdary, Pratima, Millar, Carolyn M., Hart, Dan, Keeling, David, van Moort, Iris, Bukkems, Laura H, Hazendonk, Hendrika C A M, van der Bom, Johanna G, Laros-van Gorkom, Britta A P, Beckers, Erik A M, van der Meer, Felix J M, Schutgens, Roger E G, Leebeek, Frank W G, Mathôt, Ron A A, and Cnossen, Marjon H

Published
2021
Full Text
View/download PDF

6. Type 1 VWD classification revisited - novel insights from combined analysis of the LoVIC and WiN studies

Author

Poli Van Creveldkliniek Medisch, Child Health, Atiq, Ferdows, Blok, Robin, van Kwawegen, Calvin, Doherty, Dearbhla, Lavin, Michelle, van der Bom, Johanna G, O'Connell, Niamh M, de Meris, Joke, Ryan, Kevin, Schols, Saskia E M, Byrne, Mary B, Heubel-Moenen, Floor C J I, van Galen, Karin P M, Preston, Roger J S, Cnossen, Marjon H, Fijnvandraat, Karin, Baker, Ross Ian, Meijer, Karina, James, Paula D, Di Paola, Jorge, Eikenboom, Jeroen C J, Leebeek, Frank W G, O'Donnell, James S, Poli Van Creveldkliniek Medisch, Child Health, Atiq, Ferdows, Blok, Robin, van Kwawegen, Calvin, Doherty, Dearbhla, Lavin, Michelle, van der Bom, Johanna G, O'Connell, Niamh M, de Meris, Joke, Ryan, Kevin, Schols, Saskia E M, Byrne, Mary B, Heubel-Moenen, Floor C J I, van Galen, Karin P M, Preston, Roger J S, Cnossen, Marjon H, Fijnvandraat, Karin, Baker, Ross Ian, Meijer, Karina, James, Paula D, Di Paola, Jorge, Eikenboom, Jeroen C J, Leebeek, Frank W G, and O'Donnell, James S

Published
2024

7. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A

Author

Poli Van Creveldkliniek Medisch, Regenerative Medicine and Stem Cells, Oomen, Ilja, Verhagen, Marieke, Miranda, Mariarosaria, Allacher, Peter, Beckers, Erik A M, Blijlevens, Nicole M A, van der Bom, Johanna G, Coppens, Michiel, Driessens, Mariëtte, Eikenboom, Jeroen C J, Fijnvandraat, Karin, Hassan, Shermarke, van Heerde, Waander L, Hooimeijer, H Louise, Jansen, Joop H, Kaijen, Paul, Leebeek, Frank W G, Meijer, Daniëlle, Paul, Helmut, Rijpma, Sanna R, Rosendaal, Frits R, Smit, Cees, van Vulpen, Lize F D, Voorberg, Jan, Schols, Saskia E M, Gouw, Samantha C, Poli Van Creveldkliniek Medisch, Regenerative Medicine and Stem Cells, Oomen, Ilja, Verhagen, Marieke, Miranda, Mariarosaria, Allacher, Peter, Beckers, Erik A M, Blijlevens, Nicole M A, van der Bom, Johanna G, Coppens, Michiel, Driessens, Mariëtte, Eikenboom, Jeroen C J, Fijnvandraat, Karin, Hassan, Shermarke, van Heerde, Waander L, Hooimeijer, H Louise, Jansen, Joop H, Kaijen, Paul, Leebeek, Frank W G, Meijer, Daniëlle, Paul, Helmut, Rijpma, Sanna R, Rosendaal, Frits R, Smit, Cees, van Vulpen, Lize F D, Voorberg, Jan, Schols, Saskia E M, and Gouw, Samantha C

Published
2024

8. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease

Author

Poli Van Creveldkliniek Medisch, Verhagen, Marieke J A, van Balen, Erna C, Blijlevens, Nicole M A, Coppens, Michiel, van Heerde, Waander L, Leebeek, Frank W G, Rijpma, Sanna R, van Vulpen, Lize F D, Gouw, Samantha C, Schols, Saskia E M, Poli Van Creveldkliniek Medisch, Verhagen, Marieke J A, van Balen, Erna C, Blijlevens, Nicole M A, Coppens, Michiel, van Heerde, Waander L, Leebeek, Frank W G, Rijpma, Sanna R, van Vulpen, Lize F D, Gouw, Samantha C, and Schols, Saskia E M

Published
2024

9. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A

Author

Oomen, Ilja, primary, Verhagen, Marieke, additional, Miranda, Mariarosaria, additional, Allacher, Peter, additional, Beckers, Erik A. M., additional, Blijlevens, Nicole M. A., additional, Bom, Johanna G. van der, additional, Coppens, Michiel, additional, Driessens, Mariëtte, additional, Eikenboom, Jeroen C. J., additional, Fijnvandraat, Karin, additional, Hassan, Shermarke, additional, van Heerde, Waander L., additional, Hooimeijer, H. Louise, additional, Jansen, Joop H., additional, Kaijen, Paul, additional, Leebeek, Frank W. G., additional, Meijer, Daniëlle, additional, Paul, Helmut, additional, Rijpma, Sanna R., additional, Rosendaal, Frits R., additional, Smit, Cees, additional, van Vulpen, Lize F. D., additional, Voorberg, Jan, additional, Schols, Saskia E. M., additional, and Gouw, Samantha C., additional

Published
2024
Full Text
View/download PDF

12. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy.

Author

Itzler, Robbin, Buckner, Tyler W., Leebeek, Frank W. G., Miller, Joel, Recht, Michael, Drelich, Douglass, Monahan, Paul E., and Pipe, Steven W.

Subjects
CLINICAL trials, GENE therapy, BLOOD coagulation factor IX, QUALITY of life, PATIENT reported outcome measures
Abstract

Introduction: For people with haemophilia B (PwHB), bleeding may occur despite prophylaxis, negatively affecting health‐related quality of life (HRQoL). The pivotal phase 3 HOPE‐B trial investigating the adeno‐associated virus gene transfer product, etranacogene dezaparvovec (EDZ), demonstrated sustained factor IX (FIX) activity and bleed protection in PwHB with baseline FIX levels ≤2%. Aim: Assess how EDZ affects HRQoL in HOPE‐B trial participants. Methods: HRQoL was evaluated using generic and disease‐specific patient reported outcomes (PROs) including the EQ‐5D‐5L and the Hem‐A‐QoL questionnaires. Mean domain and total scores were compared 6 months pre‐ and the first 2 years post‐EDZ administration using repeated measures linear mixed models. The percentage of participants with minimal clinically important improvements in HRQoL was also evaluated. Results: Two years post‐EDZ, there were nominally significant increases in the least squares (LS) mean score for the EQ‐5D‐5L Index Value (.04; p =.0129), reflecting better HRQoL. Nominally significant decreases in the LS mean scores, reflecting better HRQoL, were also found for the Hem‐A‐QoL total score (−6.0; p <.0001) and the Treatment (−13.94; p <.0001), Feelings (−9.01; p <.0001), Future (−6.45; p =.0004) and Work/School (−5.21; p =.0098) domains. The percentage of participants with ≥15‐point improvement ranged from 45.83% (95% CI: 31.37%, 60.83%) for Treatment to 13.89% (95% CI: 4.67%, 29.50%) for Family Planning. Results were similar for Year 1. Conclusion: In conclusion, gene therapy with EDZ improved HRQoL in the first and second years in several Hem‐A‐QoL domains, including Treatment, Feelings, Work/School and Future domains, whereas improvement in other aspects of HRQoL were not demonstrated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients.

Author

Romano, Lorenzo G. R., Schütte, Lisette M., van Hest, Reinier M., Meijer, Karina, Laros‐van Gorkom, Britta A. P., Nieuwenhuizen, Laurens, Eikenboom, Jeroen, Heubel‐Moenen, Floor C. J. I., Uitslager, Nanda, Coppens, Michiel, Fijnvandraat, Karin, Driessens, Mariëtte H. E., Polinder, Suzanne, Cnossen, Marjon H., Leebeek, Frank W. G., Mathôt, Ron A. A., and Kruip, Marieke J. H. A.

Subjects
HEMOPHILIACS, BLOOD coagulation factor VIII, DESMOPRESSIN, HEMOPHILIA treatment, HEMOPHILIA
Abstract

Introduction: Non‐severe haemophilia A patient can be treated with desmopressin or factor VIII (FVIII) concentrate. Combining both may reduce factor consumption, but its feasibility and safety has never been investigated. Aim: We assessed the feasibility and safety of combination treatment in nonsevere haemophilia A patients. Methods: Non‐severe, desmopressin responsive, haemophilia A patients were included in one of two studies investigating peri‐operative combination treatment. In the single‐arm DAVID study intravenous desmopressin (0.3 μg/kg) once‐a‐day was, after sampling, immediately followed by PK‐guided FVIII concentrate, for maximally three consecutive days. The Little DAVID study was a randomized trial in patients undergoing a minor medical procedure, whom received either PK‐guided combination treatment (intervention arm) or PK‐guided FVIII concentrate only (standard arm) up to 2 days. Dose predictions were considered accurate if the absolute difference between predicted and measured FVIII:C was ≤0.2 IU/mL. Results: In total 32 patients (33 procedures) were included. In the DAVID study (n = 21), of the FVIII:C trough levels 73.7% (14/19) were predicted accurately on day 1 (D1), 76.5% (13/17) on D2. On D0, 61.9% (13/21) of peak FVIII:C levels predictions were accurate. In the Little DAVID study (n = 12), on D0 83.3% (5/6) FVIII:C peak levels for both study arms were predicted accurately. Combination treatment reduced preoperative FVIII concentrate use by 47% versus FVIII monotherapy. Desmopressin side effects were mild and transient. Two bleeds occurred, both despite FVIII:C > 1.00 IU/mL. Conclusion: Peri‐operative combination treatment with desmopressin and PK‐guided FVIII concentrate dosing in nonsevere haemophilia A is feasible, safe and reduces FVIII consumption. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study

Author

Brands, Martijn R., primary, Janssen, Ebony A. M., additional, Cnossen, Marjon H., additional, Smit, Cees, additional, van Vulpen, Lize F. D., additional, van der Valk, Paul R., additional, Eikenboom, Jeroen, additional, Heubel‐Moenen, Floor C. J. I., additional, Hooimeijer, Louise, additional, Ypma, Paula, additional, Nieuwenhuizen, Laurens, additional, Coppens, Michiel, additional, Schols, Saskia E. M., additional, Laros‐van Gorkom, Britta A. P., additional, Leebeek, Frank W. G., additional, Driessens, Mariëtte H. E., additional, Rosendaal, Frits R., additional, van der Bom, Johanna G., additional, Fijnvandraat, Karin, additional, and Gouw, Samantha C., additional

Published
2023
Full Text
View/download PDF

18. Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study

Author

Poli Van Creveldkliniek Medisch, Brands, Martijn R, Janssen, Ebony A M, Cnossen, Marjon H, Smit, Cees, van Vulpen, Lize F D, van der Valk, Paul R, Eikenboom, Jeroen, Heubel-Moenen, Floor C J I, Hooimeijer, Louise, Ypma, Paula, Nieuwenhuizen, Laurens, Coppens, Michiel, Schols, Saskia E M, Laros-van Gorkom, Britta A P, Leebeek, Frank W G, Driessens, Mariëtte H E, Rosendaal, Frits R, van der Bom, Johanna G, Fijnvandraat, Karin, Gouw, Samantha C, Poli Van Creveldkliniek Medisch, Brands, Martijn R, Janssen, Ebony A M, Cnossen, Marjon H, Smit, Cees, van Vulpen, Lize F D, van der Valk, Paul R, Eikenboom, Jeroen, Heubel-Moenen, Floor C J I, Hooimeijer, Louise, Ypma, Paula, Nieuwenhuizen, Laurens, Coppens, Michiel, Schols, Saskia E M, Laros-van Gorkom, Britta A P, Leebeek, Frank W G, Driessens, Mariëtte H E, Rosendaal, Frits R, van der Bom, Johanna G, Fijnvandraat, Karin, and Gouw, Samantha C

Published
2023

19. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

Author

Poli Van Creveldkliniek Medisch, Pipe, Steven W, Leebeek, Frank W G, Recht, Michael, Key, Nigel S, Castaman, Giancarlo, Miesbach, Wolfgang, Lattimore, Susan, Peerlinck, Kathelijne, Van der Valk, Paul, Coppens, Michiel, Kampmann, Peter, Meijer, Karina, O'Connell, Niamh, Pasi, K John, Hart, Daniel P, Kazmi, Rashid, Astermark, Jan, Hermans, Cedric R J R, Klamroth, Robert, Lemons, Richard, Visweshwar, Nathan, von Drygalski, Annette, Young, Guy, Crary, Shelley E, Escobar, Miguel, Gomez, Esteban, Kruse-Jarres, Rebecca, Quon, Doris V, Symington, Emily, Wang, Michael, Wheeler, Allison P, Gut, Robert, Liu, Ying P, Dolmetsch, Ricardo E, Cooper, David L, Li, Yanyan, Goldstein, Brahm, Monahan, Paul E, Poli Van Creveldkliniek Medisch, Pipe, Steven W, Leebeek, Frank W G, Recht, Michael, Key, Nigel S, Castaman, Giancarlo, Miesbach, Wolfgang, Lattimore, Susan, Peerlinck, Kathelijne, Van der Valk, Paul, Coppens, Michiel, Kampmann, Peter, Meijer, Karina, O'Connell, Niamh, Pasi, K John, Hart, Daniel P, Kazmi, Rashid, Astermark, Jan, Hermans, Cedric R J R, Klamroth, Robert, Lemons, Richard, Visweshwar, Nathan, von Drygalski, Annette, Young, Guy, Crary, Shelley E, Escobar, Miguel, Gomez, Esteban, Kruse-Jarres, Rebecca, Quon, Doris V, Symington, Emily, Wang, Michael, Wheeler, Allison P, Gut, Robert, Liu, Ying P, Dolmetsch, Ricardo E, Cooper, David L, Li, Yanyan, Goldstein, Brahm, and Monahan, Paul E

Published
2023

20. Colorectal cancer screening in patients with inherited bleeding disorders: high cancer detection rate in hemophilia patients

Author

Poli Van Creveldkliniek Medisch, Kempers, Eva K, van Kwawegen, Calvin B, de Meris, Joke, Spaander, Manon C W, Schols, Saskia E M, Ypma, Paula F, Heubel-Moenen, Floor C J I, van Vulpen, Lize F D, Coppens, Michiel, van der Bom, Johanna G, Fijnvandraat, Karin, Meijer, Karina, Eikenboom, Jeroen, Gouw, Samantha C, Leebeek, Frank W G, Kruip, Marieke J H A, Poli Van Creveldkliniek Medisch, Kempers, Eva K, van Kwawegen, Calvin B, de Meris, Joke, Spaander, Manon C W, Schols, Saskia E M, Ypma, Paula F, Heubel-Moenen, Floor C J I, van Vulpen, Lize F D, Coppens, Michiel, van der Bom, Johanna G, Fijnvandraat, Karin, Meijer, Karina, Eikenboom, Jeroen, Gouw, Samantha C, Leebeek, Frank W G, and Kruip, Marieke J H A

Published
2023

21. In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype

Author

Poli Van Creveldkliniek Medisch, Verhagen, Marieke J A, van Heerde, Waander L, van der Bom, Johanna G, Beckers, Erik A M, Blijlevens, Nicole M A, Coppens, Michiel, Gouw, Samantha C, Jansen, Joop H, Leebeek, Frank W G, van Vulpen, Lize F D, Meijer, Daniëlle, Schols, Saskia E M, Poli Van Creveldkliniek Medisch, Verhagen, Marieke J A, van Heerde, Waander L, van der Bom, Johanna G, Beckers, Erik A M, Blijlevens, Nicole M A, Coppens, Michiel, Gouw, Samantha C, Jansen, Joop H, Leebeek, Frank W G, van Vulpen, Lize F D, Meijer, Daniëlle, and Schols, Saskia E M

Published
2023

23. Prophylaxis with recombinant von Willebrand factor ( rVWF ) in patients with type 3 von Willebrand disease ( VWD ): results of a post hoc analysis from a phase 3 trial

Author

Leebeek, Frank W. G., primary, Peyvandi, Flora, additional, Tiede, Andreas, additional, Castaman, Giancarlo, additional, Escobar, Miguel, additional, Wang, Michael, additional, Zülfikar, Bulent, additional, Susen, Sophie, additional, Miesbach, Wolfgang, additional, Wang, Scarlett, additional, Wang, Yi, additional, Zhang, Jingmei, additional, and Özen, Gülden, additional

Published
2023
Full Text
View/download PDF

27. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease

Author

Atiq, Ferdows, primary, Heijdra, Jessica, additional, Snijders, Fleur, additional, Boender, Johan, additional, Kempers, Eva, additional, van Heerde, Waander L., additional, Maas, Dominique P. M. S. M., additional, Krouwel, Sandy, additional, Schoormans, Selene C., additional, de Meris, Joke, additional, Schols, Saskia E. M., additional, van Galen, Karin P. M., additional, van der Bom, Johanna G., additional, Cnossen, Marjon H., additional, Meijer, Karina, additional, Fijnvandraat, Karin, additional, Eikenboom, Jeroen, additional, and Leebeek, Frank W. G., additional

Published
2022
Full Text
View/download PDF

28. Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.

Author

Leebeek, Frank W. G., Peyvandi, Flora, Tiede, Andreas, Castaman, Giancarlo, Escobar, Miguel, Wang, Michael, Zülfikar, Bulent, Susen, Sophie, Miesbach, Wolfgang, Wang, Scarlett, Wang, Yi, Zhang, Jingmei, and Özen, Gülden

Subjects
*VON Willebrand factor, *CLINICAL trials, *PREVENTIVE medicine, *MEDICAL records
Abstract

Objectives: To describe efficacy/safety of recombinant von Willebrand factor (rVWF) prophylaxis in patients with type 3 von Willebrand disease (VWD). Methods: This post hoc analysis of a phase 3 open‐label trial provides a more detailed analysis of adults with type 3 VWD, categorized based on prior treatment at screening: "Prior On‐Demand (OD)" (OD VWF; ≥3 documented spontaneous bleeding events [BEs] requiring VWF in previous 12 months) or "Switch" (plasma‐derived [pd] VWF prophylaxis for ≥12 months). Annualized bleeding rates (ABRs) were evaluated during 12 months of rVWF prophylaxis versus historical data from medical records. Results: In the Prior OD group (n = 10), mean spontaneous ABR (sABR) for treated BEs was reduced by 91.6% (ratio, 0.08; 95% CI, 0.02–0.45) versus mean historical sABR. In the Switch group (n = 8), mean sABR for treated BEs was reduced by 47% (ratio, 0.53; 95% CI, 0.08–3.62). One non‐serious adverse event (AE) was considered possibly related to rVWF. No treatment‐related, fatal, or life‐threatening serious AEs were reported, and no patient developed VWF inhibitors. Conclusions: rVWF prophylaxis reduced sABR in type 3 VWD patients previously treated with OD VWF therapy, and maintained a similar level of hemostatic control in those switching from pdVWF prophylaxis to rVWF prophylaxis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. The bleeding phenotype in people with nonsevere hemophilia

Author

Kloosterman, Fabienne R., primary, Zwagemaker, Anne-Fleur, additional, Bagot, Catherine N., additional, Beckers, Erik A. M., additional, Castaman, Giancarlo, additional, Cnossen, Marjon H., additional, Collins, Peter W., additional, Hay, Charles, additional, Hof, Michel, additional, Laros-van Gorkom, Britta, additional, Leebeek, Frank W. G., additional, Male, Christoph, additional, Meijer, Karina, additional, Pabinger, Ingrid, additional, Shapiro, Susan, additional, Coppens, Michiel, additional, Fijnvandraat, Karin, additional, and Gouw,, Samantha C., additional

Published
2022
Full Text
View/download PDF

30. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Author

Leebeek, Frank W. G., primary, Peyvandi, Flora, additional, Escobar, Miguel, additional, Tiede, Andreas, additional, Castaman, Giancarlo, additional, Wang, Michael, additional, Wynn, Tung, additional, Baptista, Jovanna, additional, Wang, Yi, additional, Zhang, Jingmei, additional, Mellgård, Björn, additional, and Özen, Gülden, additional

Published
2022
Full Text
View/download PDF

31. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)

Author

Goedhart, Tine M H J, Bukkems, Laura H, Coppens, Michiel, Fijnvandraat, Karin J, Schols, Saskia E M, Schutgens, Roger E G, Eikenboom, Jeroen, Heubel-Moenen, Floor C J I, Ypma, Paula F, Nieuwenhuizen, L, Meijer, K, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H, Goedhart, Tine M H J, Bukkems, Laura H, Coppens, Michiel, Fijnvandraat, Karin J, Schols, Saskia E M, Schutgens, Roger E G, Eikenboom, Jeroen, Heubel-Moenen, Floor C J I, Ypma, Paula F, Nieuwenhuizen, L, Meijer, K, Leebeek, Frank W G, Mathôt, Ron A A, and Cnossen, Marjon H

Abstract

In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term disability. Pharmacokinetic (PK)-guided dosing can be applied to individualize factor replacement therapy, as interindividual differences in PK parameters influence factor VIII (FVIII) and FIX activity levels. PK-guided dosing may therefore lead to more optimal safeguarding of FVIII/FIX levels during prophylaxis and on demand treatment. The OPTI-CLOT TARGET study is a multicenter, nonrandomized, prospective cohort study that aims to investigate the reliability and feasibility of PK-guided prophylactic dosing of factor concentrates in hemophilia-A and -B patients in daily clinical practice. At least 50 patients of all ages on prophylactic treatment using standard half-life (SHL) and extended half-life (EHL) factor concentrates will be included during 9 months and will receive PK-guided treatment. As primary endpoint, a minimum of four FVIII/FIX levels will be compared with FVIII/FIX levels as predicted by Bayesian forecasting. Secondary endpoints are the association of FVIII and FIX levels with bleeding episodes and physical activity, expectations and experiences, economic analyses, and optimization of population PK models. This study will lead to more insight in the reliability and feasibility of PK-guided dosing in hemophilia patients. Moreover, it will contribute to personalization of treatment by greater knowledge of dosing regimens needed to prevent and treat bleeding in the individual patient and provide evidence to more clearly associate factor activity levels with bleeding risk.

Published
2022

32. Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

Author

ten Ham, Renske M. T., Walker, Sikon M., Soares, Marta O., Frederix, Geert W. J., Leebeek, Frank W. G., Fischer, Kathelijn, Coppens, Michiel, Palmer, Stephen J., ten Ham, Renske M. T., Walker, Sikon M., Soares, Marta O., Frederix, Geert W. J., Leebeek, Frank W. G., Fischer, Kathelijn, Coppens, Michiel, and Palmer, Stephen J.

Abstract

The objective was to undertake an early cost-effectiveness assessment of valoctocogene roxaparvovec (valrox; Roctavian) compared to factor (F)VIII prophylaxis or emicizumab (Hemlibra; Roche HQ, Bazel, Switzerland) in patients with severe Hemophilia A (HA) without FVIII-antibodies. We also aimed to incorporate and quantify novel measures of value such as treatment durability, maximum value-based price (MVBP) and break-even time (ie, time until benefits begin to offset upfront payment). We constructed a Markov model to model bleeds over time which were linked to costs and quality-of-life decrements. In the valrox arm, FVIII over time was estimated combining initial effect and treatment waning and then linked to bleeds. In FVIII and emicizumab arms, bleeds were based on trial evidence. Evidence and assumptions were validated using expert elicitation. Model robustness was tested via sensitivity analyses. A Dutch societal perspective was applied with a 10-year time horizon. Valrox in comparison to FVIII, and emicizumab showed small increases in quality-adjusted life years at lower costs, and were therefore dominant. Valrox' base case MVBP was estimated at €2.65 million/treatment compared to FVIII and €3.5 million/treatment versus emicizumab. Mean break-even time was 8.03 years compared to FVIII and 5.68 years to emicizumab. Early modeling of patients with HA in The Netherlands treated with valrox resulted in estimated improved health and lower cost compared to prophylactic FVIII and emicizumab. We also demonstrated feasibility of incorporation of treatment durability and novel outcomes such as value-based pricing scenarios and break-even time. Future work should aim to better characterize uncertainties and increase translation of early modeling to direct research efforts.

Published
2022

33. Von Willebrand disease type 2M:Correlation between genotype and phenotype

Author

Maas, Dominique P.M.S.M., Atiq, Ferdows, Blijlevens, Nicole M.A., Brons, Paul P T, Krouwel, Sandy, Laros-van Gorkom, Britta A.P., Leebeek, Frank W G, Nieuwenhuizen, Laurens, Schoormans, Selene C.M., Simons, Annet, Meijer, Daniëlle, van Heerde, Waander L., Schols, Saskia E.M., Maas, Dominique P.M.S.M., Atiq, Ferdows, Blijlevens, Nicole M.A., Brons, Paul P T, Krouwel, Sandy, Laros-van Gorkom, Britta A.P., Leebeek, Frank W G, Nieuwenhuizen, Laurens, Schoormans, Selene C.M., Simons, Annet, Meijer, Daniëlle, van Heerde, Waander L., and Schols, Saskia E.M.

Abstract

Background: An appropriate clinical diagnosis of von Willebrand disease (VWD) can be challenging because of a variable bleeding pattern and laboratory phenotype. Genotyping is a powerful diagnostic tool and may have an essential role in the diagnostic field of VWD. Objectives: To unravel the clinical and laboratory heterogeneity of genetically confirmed VWD type 2M patients and to investigate their relationship. Methods: Patients with a confirmed VWD type 2M genetic variant in the A1 or A3 domain of von Willebrand factor (VWF) and normal or only slightly aberrant VWF multimers were selected from all subjects genotyped at the Radboud university medical center because of a high suspicion of VWD. Bleeding scores and laboratory results were analyzed. Results: Fifty patients had a clinically relevant genetic variant in the A1 domain. Median bleeding score was 5. Compared with the nationwide Willebrand in the Netherlands study type 2 cohort, bleeding after surgery or delivery was reported more frequently and mucocutaneous bleedings less frequently. Median VWF activity/VWF antigen (VWF:Act/VWF:Ag) ratio was 0.32, whereas VWF collagen binding activity/VWF antigen (VWF:CB/VWF:Ag) ratio was 0.80. Variants in the A3 domain were only found in two patients with low to normal VWF:Act/VWF:Ag ratios (0.45, 1.03) and low VWF:CB/VWF:Ag ratios (0.45, 0.63). Conclusion: Genetically confirmed VWD type 2M patients have a relatively mild clinical phenotype, except for bleeding after surgery and delivery. Laboratory phenotype is variable and depends on the underlying genetic variant. Addition of genotyping to the current phenotypic characterization may improve diagnosis and classification of VWD.

Published
2022

34. Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study

Author

Poli Van Creveldkliniek Medisch, van Balen, Erna C, Hassan, Shermarke, Smit, Cees, Driessens, Mariette H E, Beckers, Erik A M, Coppens, Michiel, Eikenboom, Jeroen C, Hooimeijer, Hélène L, Leebeek, Frank W G, Mauser-Bunschoten, Evelien P, van Vulpen, Lize F D, Schols, Saskia E M, Rosendaal, Frits R, van der Bom, Johanna G, Gouw, Samantha C, Poli Van Creveldkliniek Medisch, van Balen, Erna C, Hassan, Shermarke, Smit, Cees, Driessens, Mariette H E, Beckers, Erik A M, Coppens, Michiel, Eikenboom, Jeroen C, Hooimeijer, Hélène L, Leebeek, Frank W G, Mauser-Bunschoten, Evelien P, van Vulpen, Lize F D, Schols, Saskia E M, Rosendaal, Frits R, van der Bom, Johanna G, and Gouw, Samantha C

Published
2022

35. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)

Author

Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Infection & Immunity, Goedhart, Tine M H J, Bukkems, Laura H, Coppens, Michiel, Fijnvandraat, Karin J, Schols, Saskia E M, Schutgens, Roger E G, Eikenboom, Jeroen, Heubel-Moenen, Floor C J I, Ypma, Paula F, Nieuwenhuizen, L, Meijer, K, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H, Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Infection & Immunity, Goedhart, Tine M H J, Bukkems, Laura H, Coppens, Michiel, Fijnvandraat, Karin J, Schols, Saskia E M, Schutgens, Roger E G, Eikenboom, Jeroen, Heubel-Moenen, Floor C J I, Ypma, Paula F, Nieuwenhuizen, L, Meijer, K, Leebeek, Frank W G, Mathôt, Ron A A, and Cnossen, Marjon H

Published
2022

36. Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

Author

HEE, Child Health, JC onderzoeksprogramma Methodologie, Poli Van Creveldkliniek Medisch, Circulatory Health, Ten Ham, Renske M T, Walker, Sikon M, Soares, Marta O, Frederix, Geert W J, Leebeek, Frank W G, Fischer, Kathelijn, Coppens, Michiel, Palmer, Stephen J, HEE, Child Health, JC onderzoeksprogramma Methodologie, Poli Van Creveldkliniek Medisch, Circulatory Health, Ten Ham, Renske M T, Walker, Sikon M, Soares, Marta O, Frederix, Geert W J, Leebeek, Frank W G, Fischer, Kathelijn, Coppens, Michiel, and Palmer, Stephen J

Published
2022

38. Modelling benefits, costs and affordability of a novel gene therapy in hemophilia A

Author

Ten Ham, Renske M T, Walker, Simon M, Soares, Marta O, Frederix, Geert W J, Leebeek, Frank W G, Fischer, Kathelijn, Coppens, Michiel, and Palmer, Stephen J

Abstract

The objective was to assess undertake an early cost-effectiveness assessment of valoctocogene roxaparvovec (valrox;Roctavian®) compared to factor (F)VIII prophylaxis or emicizumab (Hemlibra®) in patients with severe Hemophilia A (HA) without FVIII-antibodies. Secondary, weWe also aimed to incorporate and quantify novel measures of value such as treatment durability, maximum value-based price (MVBP) and break-even time (i.e., time until benefits begin to offset upfront payment). We constructed a A Markov-model was constructed to model bleeds over time which were linked to costs and quality-of-life decrements. In the valrox arm, FVIII% over time were first estimated combining initial effect and treatment waning and then linked to bleeds. In FVIII- and emicizumab-arms, bleeds were based on trial evidence. Evidence and assumptions were validated using via expert elicitation. Model robustness was tested via sensitivity analyses. A Dutch societal perspective was applied with a 10-year time-horizon. Valrox in comparison to FVIII, and emicizumab showed small increases in quality-adjusted life years atand lower costs, and was therefore dominant. Valrox’ base case MVBP was estimated at €2.65 million/treatment compared to FVIII and €3.5 million/treatment versus to emicizumab. Mean break-even time was 8.03 years compared to FVIII and 5.68 years to emicizumab. Early modelling cost-effectiveness analysis Treatment of patients with HA in the Netherlands treated with valrox was estimated to resultresulted in estimated improved health and lower cost compared to prophylactic FVIII and emicizumab. We also demonstrated feasibility to of incorporation ofmodelincorporate treatment durability was demonstrated and , as well as quantification of novel outcomes such as value-based pricing scenarios and break-even ti¬me. However, more work is needed to beter characterize uncertainties, define affordability and increase informativeness for decision making. Future work should aim to better characterize uncertainties and increase translation of early economic evaluationsmodelling to direct research efforts.

Published
2022

39. SYMPHONYconsortium: Orchestrating personalized treatment for patients with bleeding disorders

Author

Cnossen, Marjon H., Moort, Iris, Reitsma, Simone H., Maat, Moniek P. M., Schutgens, Roger E. G., Urbanus, Rolf T., Lingsma, Hester F., Mathot, Ron A. A., Gouw, Samantha C., Meijer, Karina, Bredenoord, Annelien L., Graaf, Rieke, Fijnvandraat, Karin, Meijer, Alexander B., Akker, Emile, Bierings, Ruben, Eikenboom, Jeroen C. J., Biggelaar, Maartje, Haas, Masja, Voorberg, Jan, Leebeek, Frank W. G., Cnossen, Marjon H., Reitsma, Simone H., Haas, Masja, Biggelaar, Maartje, Leebeek, Frank W. G., Voorberg, Jan, Maat, Moniek P. M., Schutgens, Roger E. G., Urbanus, Rolf T., Lingsma, Hester F., Mathot, Ron A. A., Gouw, Samantha C., Meijer, Karina, Bredenoord, Annelien L., Graaf, Rieke, Fijnvandraat, Karin, Meijer, Alexander B., Akker, Emile, Bierings, Ruben, Eikenboom, Jeroen C. J., Moort, Iris, Arisz, Ryanne A., Zivkovic, Minka, Hoorn, E. Shannon, Bukkems, Laura H., Goedhart, Tine M. C. H. J., Romano, Lorenzo G. R., Al Arashi, Wala, Cloesmeijer, Michael E., Janssen, Alexander, Brands, Martijn R., Baas, Lieke, Castillo Alferez, Jessica, Zhang, Huan, Laan, Sebastiaan N. J., Boender, Johan, Bom, Johanna G., Bos, Mettine H. A., Burdorf, Lex, Coppens, Michiel, Driessens, Mariette, Fischer, Kathelijne F., Haverman, Lotte, Hazelzet, Jan A., Huisman, Elise J., Jansen, Natalie, Jong, Sean, Kruip, Marieke, Leeuwen, Nikki, Meer, Felix, Meijer, Stephan, Amstel, Hans Kristian Ploos, Polinder, Suzanne, Schols, Saskia E. M., Wijfjes, Guus, Kluft, Kees, Heerde, Waander L., Goedhart, Geertje, Uyl, Carin, Timp, Jasmijn, Stekelenburg, Anke, Moenen, Floor, Ypma, Paula, Nieuwenhuizen, Laurens, and Plat, Arnoud

Abstract

Treatment choices for individual patients with an inborn bleeding disorder are increasingly challenging due to increasing options and rising costs for society. We have initiated an integrated interdisciplinary national research program. The SYMPHONY consortium strives to orchestrate personalized treatment in patients with an inborn bleeding disorder, by unraveling the mechanisms behind interindividual variations of bleeding phenotype. The SYMPHONY consortium will investigate patients with an inborn bleeding disorder, both diagnosed and not yet diagnosed. Research questions are categorized under the themes: (1) diagnosis, (2) treatment, and (3) fundamental research, and consist of work packages addressing specific domains. Importantly, collaborations between patients and talented researchers from different areas of expertise promise to augment the impact of the SYMPHONY consortium, leading to unique interactions and intellectual property. SYMPHONY will perform research on all aspects of care, treatment individualization in patients with inborn bleeding disorders, as well as diagnostic innovations and results of molecular genetics and cellular model technology with regard to the hemostatic process. We believe that these research investments will lead to health‐care innovations with long‐term clinical and societal impact. This consortium has been made possible by a governmental, competitive grant from the Netherlands Organization for Scientific Research (NWO) within the framework of the NWA‐ORC Call grant agreement NWA.1160.18.038.

Published
2022
Full Text
View/download PDF

41. Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study

Author

Heijdra, Jessica M, primary, Al Arashi, Wala, additional, de Jager, Nico C B, additional, Cloesmeijer, Michael E, additional, Bukkems, Laura H, additional, Zwaan, Christian M, additional, Leebeek, Frank W G, additional, Mathôt, Ron A A, additional, and Cnossen, Marjon H, additional

Published
2022
Full Text
View/download PDF

42. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature

Author

Brignardello-Petersen, Romina, primary, El Alayli, Abdallah, additional, Husainat, Nedaa, additional, Kalot, Mohamad, additional, Shahid, Shaneela, additional, Aljabirii, Yazan, additional, Britt, Alec, additional, Alturkmani, Hani, additional, El-Khechen, Hussein, additional, Motaghi, Shahrzad, additional, Roller, John, additional, Dimassi, Ahmad, additional, Abughanimeh, Omar, additional, Madoukh, Bader, additional, Arapshian, Alice, additional, Grow, Jean M., additional, Kouides, Peter, additional, Laffan, Michael, additional, Leebeek, Frank W. G., additional, O’Brien, Sarah H., additional, Tosetto, Alberto, additional, James, Paula D., additional, Connell, Nathan T., additional, Flood, Veronica, additional, and Mustafa, Reem A., additional

Published
2022
Full Text
View/download PDF

43. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)

Author

Goedhart, Tine M.H.J., additional, Bukkems, Laura H., additional, Coppens, Michiel, additional, Fijnvandraat, Karin J., additional, Schols, Saskia E.M., additional, Schutgens, Roger E.G., additional, Eikenboom, Jeroen, additional, Heubel-Moenen, Floor C.J.I., additional, Ypma, Paula F., additional, Nieuwenhuizen, L., additional, Meijer, K., additional, Leebeek, Frank W. G., additional, Mathôt, Ron A.A., additional, and Cnossen, Marjon H., additional

Published
2022
Full Text
View/download PDF

44. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress

Author

Krishnaswamy, Sriram, Ageno, Walter, Arabi, Yaseen, Barbui, Tiziano, Cannegieter, Suzanne, Carrier, Marc, Cleuren, Audrey C., Collins, Peter, Panicot‐Dubois, Laurence, Freedman, Jane E., Freson, Kathleen, Hogg, Philip, James, Andra H., Kretz, Colin A., Lavin, Michelle, Leebeek, Frank W. G., Li, Weikai, Maas, Coen, Machlus, Kellie, Makris, Michael, Martinelli, Ida, Medved, Leonid, Neerman‐Arbez, Marguerite, O’Donnell, James S., O'Sullivan, Jamie, Rajpurkar, Madhvi, Schroeder, Verena, Spiegel, Paul Clinton, Stanworth, Simon J., Green, Laura, and Undas, Anetta

Subjects
Illustrated Review, education, Illustrated Reviews, 610 Medicine & health
Abstract

This year's Congress of the International Society of Thrombosis and Haemostasis (ISTH) was hosted virtually from Philadelphia July 17–21, 2021. The conference, now held annually, highlighted cutting‐edge advances in basic, population and clinical sciences of relevance to the Society. Despite being held virtually, the 2021 congress was of the same scope and quality as an annual meeting held in person. An added feature of the program is that talks streamed at the designated times will then be available on‐line for asynchronous viewing. The program included 77 State of the Art (SOA) talks, thematically grouped in 28 sessions, given by internationally recognized leaders in the field. The SOA speakers were invited to prepare brief illustrated reviews of their talks that were peer reviewed and are included in this article. The topics, across the main scientific themes of the congress, include Arterial Thromboembolism, Coagulation and Natural Anticoagulants, COVID‐19 and Coagulation, Diagnostics and Omics, Fibrinogen, Fibrinolysis and Proteolysis, Hemophilia and Rare Bleeding Disorders, Hemostasis in Cancer, Inflammation and Immunity, Pediatrics, Platelet Disorders, von Willebrand Disease and Thrombotic Angiopathies, Platelets and Megakaryocytes, Vascular Biology, Venous Thromboembolism and Women's Health. These illustrated capsules highlight the major scientific advances with potential to impact clinical practice. Readers are invited to take advantage of the excellent educational resource provided by these illustrated capsules. They are also encouraged to use the image in social media to draw attention to the high quality and impact of the science presented at the congress.

Published
2021

46. BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease

Author

Atiq, Ferdows, Fijnvandraat, Karin, van Galen, Karin P. M., Laros-van Gorkom, Britta A. P., Meijer, Karina, de Meris, Joke, Coppens, Michiel, Mauser-Bunschoten, Eveline P., Cnossen, Marjon H., van der Bom, Johanna G., Eikenboom, Jeroen, Leebeek, Frank W. G., Coppens, M., Kors, A., Zweegman, S., de Meris, J., Goverde, G. J., Jonkers, M. H., Dors, N., Nijziel, M. R., Nieuwenhuizen, L., Meijer, K., Tamminga, R. Y. J., van der LindenHagaZiekenhuis, P. W., Ypma, P. F., Eikenboom, H. C. J., van der Bom, J. G., Smiers, F. J. W., Granzen, B., Hamulyák, K., Brons, P., Laros‐van Gorkom, B. A. P., Leebeek, F. W. G., Cnossen, M. H., Atiq, F., Mauser-Bunschoten, E. P., van Galen, K. P. M., Hematology, Pediatrics, Paediatric Haematology, ACS - Pulmonary hypertension & thrombosis, Vascular Medicine, ARD - Amsterdam Reproduction and Development, VU University medical center, Kindergeneeskunde, MUMC+: MA Medische Staf Kindergeneeskunde (9), RS: FHML non-thematic output, and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Subjects
Male, medicine.medical_specialty, Letter, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], E–Only Articles, Hemorrhage, von Willebrand Disease, Type 2, von Willebrand Disease, Type 1, Body Mass Index, Text mining, Internal medicine, von Willebrand Factor, Correspondence, Von Willebrand disease, Medicine, Humans, In patient, Hematology, Factor VIII, business.industry, Middle Aged, Blood coagulation factors, medicine.disease, Phenotype, Immunology, Female, business, Body mass index
Abstract

Contains fulltext : 208376.pdf (Publisher’s version ) (Open Access)

Published
2019

49. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

Author

Baronciani, Luciano, primary, Peake, Ian, additional, Schneppenheim, Reinhard, additional, Goodeve, Anne, additional, Ahmadinejad, Minoo, additional, Badiee, Zahra, additional, Baghaipour, Mohammad-Reza, additional, Benitez, Olga, additional, Bodó, Imre, additional, Budde, Ulrich, additional, Cairo, Andrea, additional, Castaman, Giancarlo, additional, Eshghi, Peyman, additional, Goudemand, Jenny, additional, Hassenpflug, Wolf, additional, Hoorfar, Hamid, additional, Karimi, Mehran, additional, Keikhaei, Bijan, additional, Lassila, Riitta, additional, Leebeek, Frank W. G., additional, Lopez Fernandez, Maria Fernanda, additional, Mannucci, Pier Mannuccio, additional, Marino, Renato, additional, Nikšić, Nikolas, additional, Oyen, Florian, additional, Santoro, Cristina, additional, Tiede, Andreas, additional, Toogeh, Gholamreza, additional, Tosetto, Alberto, additional, Trossaert, Marc, additional, Zetterberg, Eva M. K., additional, Eikenboom, Jeroen, additional, Federici, Augusto B., additional, and Peyvandi, Flora, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results